Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesEndocrinologyAetna Somatostatin Analogs Coverage & Prior Auth |…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0693

    Somatostatin Analogs

    Customize your policy alerts

    Sign up for Aetna Policy 0693 alerts

    Get alerted when Policy 0693 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Policy governing medical necessity, precertification, indications, continuation criteria, and dosing guidance for somatostatin analog injections for Aetna commercial medical plans.

    Policy Summary
    PayerAetna
    PolicySomatostatin Analogs
    Policy CodePolicy 0693
    Change TypeNo material change
    Effective DateDec 7, 2004
    Last ReviewJul 1, 2023
    Next Review DateApr 25, 2024
    Key ActionPrecertification required for octreotide, lanreotide, and pasireotide products; call or fax per policy.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Precertification requiredProducts requiring precertification
    MultipleDistinct indications covered for octreotide
    Cushing's diseasePasireotide covered indication
    30+Experimental/investigational indications listed
    J2353,J1930,J2502HCPCS codes mentioned
    07/01/2023Policy last reviewed

    Coverage Criteria for Somatostatin Analogs

    inv-31: VIPomas (symptomatic control)

    Aetna considers somatostatin analog therapy (e.g., octreotide or lanreotide) medically necessary for symptomatic control of VIPomas (vasoactive intestinal peptide–secreting tumors) when ALL of the following are met:

    ALL of the following

    • Member has a documented diagnosis of a VIPoma (vasoactive intestinal peptide–secreting tumor) with clinically significant symptoms such as profuse watery diarrhea, electrolyte disturbances (e.g., hypokalemia), or achlorhydria consistent with WDHA syndrome; note: VIPomas are typically rare and most often pancreatic in adults but may occur in other sites.
    • Somatostatin analog therapy is being used for symptomatic control (not solely for tumor shrinkage) with the goal of reducing diarrhea and correcting electrolyte abnormalities; and
    • There is clinical documentation that the member has experienced symptom improvement or stabilization with somatostatin analog therapy (e.g., reduction in stool frequency/volume, improvement in serum electrolytes, decreased need for hospitalization or parenteral fluids) OR the member is initiating therapy and documentation supports use for symptom control when other supportive measures are inadequate or inappropriate.
    Policy Summary
    PayerAetna
    PolicySomatostatin Analogs
    Policy CodePolicy 0693
    Change TypeNo material change
    Effective DateDec 7, 2004
    Last ReviewJul 1, 2023
    Next Review DateApr 25, 2024
    Key ActionPrecertification required for octreotide, lanreotide, and pasireotide products; call or fax per policy.
    SourceLink
    On This Page
    Coverage Criteria for Somatostatin AnalogsBilling and Diagnosis CodesPrior Authorization, Documentation, and Provider RequirementsBackground and ScopeDefinitions and Clinical ThresholdsPolicy Revision History

    Billing and Diagnosis Codes

    HCPCS codes for somatostatin analogsHCPCS
    J2353Injection, octreotide, depot form for intramuscular injection, 1 mg
    J2354Injection, octreotide, nondepot form for subcutaneous or intravenous injection, 25 mcg
    J1930Injection, lanreotide, 1 mg
    J1932Injection, lanreotide, (cipla), 1 mg
    J2502Injection, pasireotide long acting, 1 mg
    HCPCS descriptive / formulation mentionHCPCS
    Bynfezia Pen (octreotide acetate)Bynfezia Pen - disposable single-patient-use subcutaneous octreotide acetate pen (no specific NDC/HCPCS code listed in policy)
    CPT codes referencedCPT
    96361-96379IV therapy, subcutaneous infusion, therapeutic injection, and home infusion/specialty drug administration
    99601-99602IV therapy, subcutaneous infusion, therapeutic injection, and home infusion/specialty drug administration (alternate ranges listed)
    96372Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular
    33615Repair of complex cardiac anomalies (simple Fontan procedure)
    33617Modified Fontan procedure
    43204Esophagoscopy with injection sclerosis of esophageal varices
    43400Ligation, direct, esophageal varices
    48150Pancreatectomy, proximal subtotal with total duodenectomy (Whipple-type); with pancreatojejunostomy
    CPT additional referencedCPT
    48152Pancreatectomy without pancreatojejunostomy
    48153Pancreatectomy, proximal subtotal with near-total duodenectomy; with pancreatojejunostomy
    48154Pancreatectomy without pancreatojejunostomy (variant)
    80420Dexamethasone suppression panel, 48 hour (laboratory panel referenced for cortisol testing)
    ICD-10 codes listed as covered if selection criteria are metICD-10
    E22.0Acromegaly and pituitary gigantism
    E24.0-E24.9Cushing's syndrome
    E34.0Carcinoid syndrome
    C25.0-C25.9Malignant neoplasm of pancreas
    C7A.010-C7B.8Malignant neuroendocrine tumors
    R19.7Diarrhea
    K91.1Postgastric surgery syndromes (Dumping syndrome)
    ICD-10 codes listed as not covered for CPB indicationsICD-10Not Covered
    C50.011-C50.929Malignant neoplasm of breast (listed as not covered for CPB indications)
    C61Malignant neoplasm of prostate (listed as not covered for CPB indications)
    C73Malignant neoplasm of thyroid gland (listed as not covered for CPB indications)
    E10.10-E13.9Diabetes mellitus (listed as not covered for CPB indications)
    E34.4Constitutional tall stature (listed as not covered)
    Drug formulations mentionedNDC | descriptive
    Bynfezia Pen (brand mention)FDA-approved octreotide acetate prefilled pen formulation (same indications as Sandostatin)
    IGF-1 — pretreatment IGF-1 requirement for acromegaly initial approval
    Pretreatment requirementHigh pretreatment IGF-1 for age and/or gender based on laboratory reference range is required for initial approval of acromegaly treatment.
    Surgical history criterionMember must have inadequate or partial response to surgery or radiotherapy, or a documented clinical reason why surgery/radiotherapy was not performed.
    Measurement basisIGF-1 interpretation must use age- and sex-specific laboratory reference ranges.
    GH/IGF-1 goals — treatment response thresholds for acromegaly
    Primary biochemical goalsTarget GH < 5 ng/mL or IGF-1 <1.9 unit/mL (males) and <2.2 unit/mL (females).
    Monitoring frequencyUse IGF-1 levels every 2 weeks to guide titration initially; reevaluate IGF-1 or GH at 6-month intervals for maintenance.
    Common effective dosing contextTypical effective subcutaneous octreotide dose is 100 mcg three times daily; titrate based on GH/IGF-1 response.
    Cortisol tests — biochemical tests used to assess Cushing's disease response
    Accepted biochemical testsUrinary free cortisol (UFC), late-night salivary cortisol (LNSC), 1 mg overnight dexamethasone suppression test (DST), or low-dose DST (2 mg/day for 48 hours).
    Response definitionContinuation may be based on lower cortisol levels since start of therapy by one of the listed tests or improvement in signs/symptoms.
    Use contextTests are used to document biochemical response for pasireotide (Signifor) and Signifor LAR in Cushing's disease continuation criteria.
    Sandostatin/Sandostatin LAR trial period — minimum trial of short-acting octreotide before switching
    Minimum trial durationPersons not currently receiving octreotide should be maintained on subcutaneous octreotide for at least 2 weeks to determine tolerance and response before switching to LAR.
    Purpose of trialDetermine both tolerability and biochemical/clinical response (identify 'responders') prior to transitioning to long-acting depot.
    Continuation when switchingFor carcinoid/VIPoma patients switching to LAR, continue subcutaneous octreotide for at least 2 weeks (some individuals may require 3–4 weeks) to avoid symptom exacerbation.
    Signifor LAR initial dose for acromegaly — dosing detail
    Initial dose (acromegaly)Start Signifor LAR 40 mg IM every 4 weeks.
    Dose escalation (acromegaly)May increase to 60 mg every 4 weeks if GH and/or age- and sex-adjusted IGF-1 levels are not normalized after 3 months and the dose is tolerated.
    Hepatic impairment noteReduce initial and maximum doses for Child-Pugh B and avoid use in Child-Pugh C (see hepatic impairment dosing).
    Signifor LAR initial dose for Cushing's disease — dosing detail
    Initial dose (Cushing's disease)Start Signifor LAR 10 mg IM every 4 weeks.
    Dose escalation (Cushing's)After 4 months, may increase up to 40 mg every 4 weeks if 24-hour UFC not normalized and the dose is tolerated.
    Hepatic impairment noteFor Child-Pugh B, recommended initial and maximum doses are reduced (avoid in Child-Pugh C).
    High-output stoma threshold — ileostomy output definition for HOS
    HOS numeric thresholdHigh-output stoma defined as ileostomy output ≥ 1.5 L per 24 hours.
    Reported incidence rangeIncidence of high-output stoma reported approximately 3% to 16% in the literature.
    Trial inclusion criterionSome HOS trials enrolled patients with ileostomy output ≥1.5 L/24 hours for study entry.
    Hypoglycemia threshold on OGTT — numeric threshold for dumping syndrome trial
    OGTT hypoglycemia thresholdHypoglycemia defined as plasma glucose < 3.3 mmol/L (60 mg/dL) during OGTT in dumping syndrome trials.
    Primary endpoint contextPhase II dumping syndrome trial used absence of hypoglycemia (<3.3 mmol/L) at 3 months as the primary endpoint.
    Clinical implicationOGTT is used to document baseline hypoglycemia and to assess response to pasireotide therapy in late dumping syndrome.
    Transfusion requirement for ANGIOPAS enrollment — enrollment transfusion threshold
    Transfusion eligibility thresholdEnrollment in ANGIOPAS required transfusion dependence of ≥ 6 units packed RBCs in the prior 6 months.
    Trial population descriptorANGIOPAS randomized patients with refractory GI angiodysplasia and substantial transfusion needs for study inclusion.
    RationaleThreshold selected to identify patients with clinically significant transfusion dependence due to recurrent bleeding.
    Success definition — ANGIOPAS — trial success metric
    ANGIOPAS success definitionSuccess defined as a decrease of at least 30% in transfused packed RBC units during the intervention period.
    Reported trial resultsPAS-LAR arm demonstrated 50% success by ITT and 83% by per-protocol analyses in ANGIOPAS.
    Clinical outcome measurePrimary outcome focused on transfusion reduction rather than complete cessation of bleeding.
    Size threshold for hepatic cyst trial — inclusion size criteria
    Size inclusion criterionTrial of pasireotide adjunct to aspiration sclerotherapy enrolled symptomatic hepatic cysts > 5 cm in diameter.
    Study timingPasireotide was administered 2 weeks before and 2 weeks after aspiration sclerotherapy in the randomized trial.
    Outcome summaryTrial found no additional benefit of pasireotide for cyst reduction or patient-reported outcomes versus placebo.
    Pasireotide dosing regimen — perioperative dosing schedule used in RCT
    Perioperative regimen (RCT)Pasireotide 900 μg subcutaneously twice daily beginning pre-operatively on the morning of surgery and continued for 7 days (14 doses).
    Intended outcomeRegimen used to reduce clinically significant post-operative pancreatic fistula, leak, or abscess (grade ≥3).
    Trial size and result contextRandomized trial (n=300) showed lower rate of grade ≥3 POPF in pasireotide group versus placebo (9% vs 21%).
    Octreotide dosing for fistula output — dosing used in case reports/series
    Common octreotide dosing for fistula outputOctreotide 100 micrograms subcutaneously three times a day is cited for high-output pancreatic fistulas or post-op management.
    Clinical roleUsed to reduce fistula output though not consistently shown to increase closure rates; supportive care remains primary.
    Evidence noteMeta-analyses and reviews suggest somatostatin analogues may reduce fistula output but have inconsistent effects on closure rates across trials.

    Prior Authorization, Documentation, and Provider Requirements

    Documentation Required

    Precertification via phone or fax is required

    Precertification of octreotide (Bynfezia Pen, Sandostatin, Sandostatin LAR), lanreotide (Somatuline), pasireotide (Signifor, Signifor LAR) is required for Aetna participating providers and members in applicable plan designs. Precertification may be obtained by phone (866-752-7021) or fax (888-267-3277). Statement of Medical Necessity (SMN) precertification forms (Specialty Pharmacy Precertification) should be used when applicable.

    • Call (866) 752-7021 or fax (888) 267-3277 for precertification
    • Use Statement of Medical Necessity (SMN) precertification forms where required
    Prior Authorization

    Prior authorization for FDA‑approved indications; document indication and disease

    Prior authorization (PA) is generally required for agents and uses described in this policy. For FDA‑approved indications (e.g., octreotide for acromegaly, carcinoid syndrome, VIPomas; lanreotide for acromegaly and GEP‑NETs; pasireotide for Cushing’s disease and acromegaly), PA decisions should align with labeled indications and relevant compendia/guidelines. Document the FDA‑approved diagnosis consistent with the drug’s labeling when requesting authorization.

    • PA should reflect FDA‑labeled uses and document the indication/diagnosis
    • Guidelines and compendia (e.g., NCCN Drug & Biologics Compendium, UpToDate, Endocrine Society) may be used to support PA decisions
    Denial Risk

    Prior authorization likely for off‑label or investigational indications

    Prior authorization is likely to be required for off‑label or investigational uses listed in the policy (for example: pasireotide for reduction of post‑operative pancreatic fistula, pasireotide for hepatic cysts, octreotide for lymphorrhea reduction, and many other off‑label indications). Off‑label requests should include supporting clinical rationale and literature or compendia citations; absence of evidence or negative trials may lead to denial.

    • Off‑label uses require explicit justification and supporting evidence
    • Investigational/experimental indications listed in the policy are not covered
    Documentation Required

    Documentation required for switching to LAR formulations

    Specific provider documentation requirements for certain scenarios: for switching from short‑acting to long‑acting (LAR) formulations document prior response and tolerance to subcutaneous octreotide (minimum trial/observation period per product labeling). For depot therapies (e.g., Sandostatin LAR, Signifor LAR, Somatuline Depot) document prior short‑acting trial when indicated and rationale for depot use.

    • Document at least 2 weeks of subcutaneous octreotide demonstrating response and tolerability before switching to Sandostatin LAR for acromegaly or carcinoid/VIPomas where labeling indicates
    • When switching to LAR formulations, include dosing history, response (GH/IGF‑1, symptom control), and tolerance
    Documentation Required

    Required clinical documentation for chyle leak

    Provider requests for management of chyle leak or chylothorax should include documentation that conservative measures were attempted and monitored (e.g., dietary modification, parenteral nutrition, pressure dressings, suction drainage), output measurements, duration, and response. Evidence for post‑surgical chyle leak is heterogeneous; reviewers may request additional data or registry/trial evidence to support therapy.

    • Document conservative management attempts (dietary modification, TPN, drainage) and objective leak output (mL/day)
    • Provide duration of conservative therapy and timing of octreotide initiation
    Prior Authorization

    Prior authorization: LVAD‑related GI bleeding

    For LVAD‑related GI bleeding, prior authorization for secondary prophylaxis with octreotide should include documentation of the index GI bleed, prior interventions (endoscopy, transfusions, angiography, embolization), anticoagulation management, and rationale for octreotide as secondary prophylaxis. Evidence is limited to retrospective analyses and case series; PA reviewers may require documentation of recurrent bleeds or failure of conventional measures.

    • Document index GI bleeding hospitalization and prior endoscopic/medical interventions
    • Document recurrent bleeding episodes and transfusion/endoscopic requirements prior to initiating octreotide for secondary prophylaxis
    Note

    Evidence limitations — POPF, hepatic cysts, and lymphorrhea not recommended

    Evidence limitations and notable negative or neutral trials to note when justifying therapy: pasireotide for prevention of post‑operative pancreatic fistula (POPF) has mixed/negative evidence in some recent studies; pasireotide did not improve cyst reduction in a randomized trial of hepatic cyst aspiration sclerotherapy; randomized data do not support octreotide for lymphorrhea reduction after oncogynecologic lymphadenectomy. Include these findings when assessing requests for these indications.

    • Pasireotide for POPF: recent prospective single‑institution data did not show reduced clinically relevant POPF (Young et al 2018)
    • Hepatic cysts: RCT (Wijnands et al 2018) showed no benefit of pasireotide adjunct to aspiration sclerotherapy
    • Lymphorrhea: RCT evidence does not support octreotide to reduce lymphorrhea after gynecologic lymphadenectomy
    Documentation Required

    Trial documentation (carcinoid syndrome)

    Trial documentation examples to support PA for carcinoid syndrome or NET symptom control: provide symptom diaries, rescue short‑acting somatostatin use frequency, objective symptom frequency (diarrhea/flushing), and prior therapy history. For depot agents used in NETs, show prior rescue medication use and symptom burden per trial‑style measures when available.

    • Include patient symptom diaries or rescue medication use rates (e.g., days using short‑acting octreotide)
    • Provide prior therapy history and objective measures used to demonstrate need for long‑acting therapy
    Documentation Required

    Perioperative use evidence limitations — surgical context required

    Perioperative use of pasireotide (to try to reduce postoperative pancreatic fistula) has mixed evidence. If requested, provide surgical context (type of pancreatectomy, duct size, validated risk scores), timing/dosing of pasireotide relative to surgery, and outcomes being targeted (CR‑POPF, drain amylase, length of stay). Reviewers may require higher‑quality trial data or institution‑level protocols to approve perioperative use.

    • Document type of pancreatic resection, validated pancreatic fistula risk score, and timing of pasireotide doses (eg, pre‑op and post‑op regimen)
    • Provide prior institutional outcomes or protocol if available
    Note

    This section contains references only; consult cited guidelines and PIs

    This section contains references only: compendia (NCCN Drug & Biologics Compendium, UpToDate), prescribing information and peer‑reviewed studies cited in the policy may be consulted to support coverage decisions; however, inclusion in the references does not guarantee coverage. Clinical Policy Bulletins assist benefit administration but do not constitute a guarantee of coverage.

    • Refer to cited guidelines, PIs, and compendia when preparing PA documentation
    • CPBs are administrative guidance — final coverage depends on plan terms
    Step Therapy

    No explicit step therapy specified here; document prior therapies and sequencing

    Operational notes: there is no explicit, uniform step‑therapy algorithm specified in this section for all agents. Specific step‑therapy requirements (for example, trial of short‑acting octreotide before LAR formulations in some labeled uses) are noted in product labeling and should be documented. Pasireotide may be considered after dopamine‑agonist failure for select prolactinomas in case reports/series, but such uses are generally investigational and require strong justification.

    • No explicit, universal step‑therapy policy is specified here — follow labeling and local plan requirements
    • Document prior dopamine‑agonist therapy and failure if requesting pasireotide for dopamine‑resistant prolactinoma (use generally investigational)

    Background and Scope

    Somatostatin analogs are synthetic peptide analogs of somatostatin that bind somatostatin receptors and are used in endocrine and neuroendocrine disorders. They are indicated for conditions including acromegaly, carcinoid syndrome and functional neuroendocrine tumors, VIPomas, certain pituitary adenomas, and other symptomatic or compendial uses; long‑acting depot formulations (LAR) provide maintenance therapy for patients who have responded to and tolerated short‑acting subcutaneous therapy.

    Definitions and Clinical Thresholds

    Acromegaly response criteria — IGF-1 thresholds and response requirements
    Pretreatment IGF-1 requirementInitial and continuation acromegaly criteria require a high pretreatment IGF-1 level for age and/or gender based on laboratory reference range.
    Continuation markerContinuation of therapy for acromegaly requires that IGF-1 level has decreased or normalized since initiation of therapy.
    Documentation expectationProvider documentation should include baseline pretreatment IGF-1 and subsequent IGF-1 results demonstrating response for authorization/continuation.
    Cushing's disease response criteria — cortisol-based continuation criteria
    Cortisol-based continuation criteriaContinuation for Cushing's disease requires lower cortisol levels since therapy start as measured by UFC, LNSC, 1 mg overnight DST, or low-dose DST (2 mg/day x48h) or improvement in signs/symptoms.
    mUFC useMean urinary free cortisol (mUFC from three 24-hour samples) was used as primary biochemical endpoint in pasireotide trials for Cushing's disease.
    Dose titration linked to testsSignifor/Signifor LAR dosing adjustments and dose escalation are guided by normalization or reduction in 24-hour UFC per trial protocols.
    Responder — definition of clinical/biochemical responder
    Clinical/biochemical responder definitionA responder is a person who demonstrates clinical and biochemical improvement (e.g., reduced GH/IGF‑1 for acromegaly; reduced UFC or improved LNSC/DST for Cushing's; symptom control for carcinoid/VIPomas) and tolerates short‑acting octreotide when applicable.
    Responder documentationDocumentation of biochemical marker improvement and clinical benefit (symptom reduction or stabilization) is required for continuation or switching to depot formulations.
    Switching prerequisiteResponder status to short-acting therapy is required before transition to long-acting depot formulations per labeling and policy guidance.
    Hepatic impairment dosing — Signifor LAR dose adjustments by Child-Pugh class
    Child-Pugh B dosing (Signifor LAR)For Signifor LAR in hepatic impairment Child-Pugh B, recommended initial dose and maximum doses are reduced (e.g., acromegaly initial 20 mg and max 40 mg; Cushing's initial 10 mg and max 20 mg as per labeling).
    Child-Pugh C recommendationAvoid use of Signifor LAR in patients with Child-Pugh class C hepatic impairment.
    Dose escalation caveatDose escalation limits for acromegaly and Cushing's disease incorporate hepatic impairment caps per prescribing information.
    Sandostatin LAR (octreotide LAR) — definition/description
    Sandostatin LAR definitionSandostatin LAR Depot is a long-acting intramuscular depot formulation of octreotide indicated for long-term maintenance in patients who have responded to and tolerated subcutaneous octreotide.
    Switching guidancePatients currently on subcutaneous octreotide can be switched to Sandostatin LAR (e.g., 20 mg IM q4w) with continued short-acting therapy for 2+ weeks as needed to maintain symptom control during transition.
    Dose limitsDoses higher than 40 mg are not recommended for Sandostatin LAR; initial switching doses vary by indication and prior therapy per product labeling.
    Compendial uses — description of compendia-supported uses
    Compendial uses overviewCompendial uses include NETs (GI, lung, thymus, pancreas), well-differentiated grade 3 NETs with favorable biology, congenital hyperinsulinism (octreotide only), AIDS-associated diarrhea, enterocutaneous fistula, short-bowel syndrome, pancreatic fistulas, pituitary adenoma, and others.
    Evidence varies by indicationSome compendial uses are supported by randomized trials (e.g., lanreotide for GEP-NET PFS), while others rely on case series or small trials, leading to investigational status for many uses.
    FDA vs compendia distinctionFDA-approved indications (e.g., acromegaly, carcinoid symptoms, VIPomas) are a subset of broader compendial uses described in clinical literature.
    High-volume vs low-volume chyle leak — threshold distinctions
    High vs low-volume chyle leakUpToDate distinguishes low-volume postoperative leaks (<1 L/day) often treated conservatively from high-volume leaks (>1 L/day) that typically need surgical repair; somatostatin/octreotide may be used as adjunct while awaiting surgery.
    Clinical management implicationHigh-output leaks (>1 L/day) are more likely to require aggressive intervention; octreotide may be temporary adjunct to reduce output.
    Trial definition overlapSome HOS studies use thresholds around 1.5 L/24h for inclusion, reflecting variation in definitions across literature.
    Somatuline Depot / Lanreotide Injection — description of formulations
    Somatuline Depot descriptionSomatuline Depot (lanreotide) is a long-acting formulation administered deep subcutaneously (120 mg q4w in pivotal trial) approved for long-term treatment of acromegaly and to improve PFS in unresectable, well- or moderately-differentiated GEP-NETs.
    Formulation noteLanreotide Injection (branded generic) has similar labeled indications and safety profile to Somatuline Depot.
    Pivotal trial dosePivotal GEP-NET trial used lanreotide 120 mg every 4 weeks for efficacy (CLARINET).
    Idiopathic Intracranial Hypertension (IIH) — definition
    IIH definitionIdiopathic intracranial hypertension (IIH) is elevated intracranial pressure without space-occupying lesion, venous sinus thrombosis, or hydrocephalus; main symptoms include headache and visual disturbances.
    Evidence noteOpen-label trial (n=26) reported symptomatic and objective improvements with octreotide, but findings are preliminary and require validation.
    Use statusLimited and mixed evidence; not established as standard therapy pending further studies.
    Progression-free survival (PFS) — definition and use in trials
    PFS definitionProgression-free survival (PFS) is time to disease progression per central radiologic review using RECIST or death; used as primary efficacy outcome in lanreotide GEP-NET trials.
    Clinical usePFS improvement with lanreotide (CLARINET) supported approval for unresectable, well- or moderately-differentiated GEP-NETs.
    Trial contextPivotal trial enrolled mostly grade 1 tumors and many patients with stable disease at baseline; results most applicable to similar populations.
    mUFC — definition and clinical use
    mUFC definitionMean urinary free cortisol (mUFC) is the mean of three 24-hour urine samples and is used as the primary biochemical endpoint in pasireotide trials for Cushing's disease.
    Trial usemUFC normalization at month 7 was the primary endpoint in the long-acting pasireotide phase 3 trial.
    InterpretationNormalization or significant reduction in mUFC supports continuation of pasireotide therapy per policy criteria.
    Dopamine-resistant prolactinoma — definition and prevalence
    Dopamine-resistant prolactinoma meaningDopamine-resistant prolactinoma refers to tumors that do not respond to dopamine-agonist therapy (approximately 10% of prolactinomas).
    Pasireotide contextCase reports suggest pasireotide may control prolactin and tumor size in selected DA-resistant prolactinomas expressing SSTR5, but evidence is limited to case reports/series.
    Evidence implicationUse remains experimental until validated in controlled studies; prior standard therapies and DA resistance should be documented.
    Functionally active NET — definition
    Functionally active NETFunctionally active NETs produce biologically active substances (peptides or serotonin) that cause clinical symptoms amenable to somatostatin analog control.
    Symptom control rateSomatostatin analogs alleviate symptoms in approximately 30–70% of patients with functioning NETs.
    Therapeutic intentTreatment aims at symptom control (flushing, diarrhea) and may have limited anti-proliferative effects depending on agent and tumor biology.
    Long‑acting repeatable (LAR) octreotide — definition
    LAR octreotide definitionLong-acting repeatable (LAR) octreotide is a monthly intramuscular depot formulation that allows once-monthly dosing for maintenance therapy after response to short-acting octreotide.
    Clinical advantageLAR formulation improves acceptability and compliance compared with multiple daily subcutaneous injections.
    Indication linkageLAR octreotide is indicated for maintenance in acromegaly, carcinoid syndrome, and VIPomas in patients who have responded to subcutaneous octreotide.
    Carcinoid syndrome — definition and symptoms
    Carcinoid syndrome definitionCarcinoid syndrome is a symptom complex (flushing, diarrhea, potential cardiac involvement) due to hormone secretion from metastatic carcinoid tumors.
    Management roleSomatostatin analogs are primary agents to control carcinoid symptoms and reduce need for short-acting rescue therapy.
    Response expectationLong-acting formulations reduce days requiring rescue medication and improve symptom control in randomized trials.
    Progression-free survival (PFS) — CLARINET context
    PFS in CLARINET contextIn CLARINET, PFS was the primary endpoint showing lanreotide significantly prolonged PFS versus placebo (HR 0.47); PFS defined as time to progression by RECIST or death.
    Trial relevancePFS used to support anti-proliferative indication of lanreotide in unresectable/metastatic GEP-NETs.
    Population specificsCLARINET enrolled largely grade 1–2, non-functioning NETs with many patients having stable disease at baseline; applicability is to similar patient profiles.
    Clinically significant post-operative pancreatic fistula — trial endpoint definition
    Clinically significant POPF definitionClinically significant post-operative pancreatic fistula defined as grade ≥3 (requiring drainage) used as primary endpoint in perioperative pasireotide trial.
    Trial endpoint implicationReduction in grade ≥3 POPF was the basis for perioperative pasireotide benefit in the randomized trial.
    Use cautionEvidence supports reduced clinically significant POPF rates in select trial populations; surgical details (duct size, procedure) influenced outcomes.
    TLV/TKV change — definition of liver/kidney volume endpoints
    TLV/TKV change definitionPercent change in total liver volume (TLV) and total kidney volume (TKV) are trial endpoints used to assess somatostatin analog effects in PKD/PLD studies.
    Clinical interpretationSomatostatin analogs reduced %TLV and %TKV growth in meta-analyses but did not change eGFR; weigh volumetric changes against clinical outcomes.
    Monitoring implicationBaseline and serial imaging to measure TLV/TKV are required in trials assessing efficacy for PKD/PLD.
    Prescribing Information — manufacturer PI references
    Prescribing information roleManufacturer prescribing information (package inserts) for Sandostatin LAR, Somatuline Depot, and Signifor/Signifor LAR provide official dosing, hepatic impairment adjustments, contraindications, and monitoring guidance used in policy.
    Documentation usePolicy cites prescribing information to support dosing recommendations and monitoring expectations (e.g., glucose monitoring with pasireotide).
    Reference examplesNovartis Sandostatin LAR and Somatuline Depot PIs and Recordati Signifor PIs are referenced in the document bibliography.
    NCCN / Guideline references — compendium and guideline citations
    Guideline/compendium citationsNational guidelines and compendia (e.g., NCCN drug compendia, Endocrine Society guidelines) are cited to support FDA-labeled and compendial uses in the policy.
    Use for oncology indicationsNCCN compendium entries are used to inform coverage for oncology-related NET indications and to align with trial populations.
    Policy integrationGuidelines and compendia inform clinical expectations for documentation, monitoring, and patient selection in prior authorization decisions.

    Policy Revision History